Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BioNTech SE - ADR (BNTX) vs Hyatt Hotels Corporation (H) Price & Performance

BioNTech SE - ADRTrade
Hyatt Hotels CorporationTrade

Price performance (Past 24H)

Key statistics

BioNTech SE - ADR vs Hyatt Hotels Corporation — how do they compare? BioNTech SE - ADR trades at $93.34 (market cap $23.31B), while Hyatt Hotels Corporation trades at $177.36 (market cap $16.27B). The key difference: BioNTech SE - ADR is the larger of the two by market cap, and Hyatt Hotels Corporation pays a 0.35% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.

BNTXH
Market Cap
$23.31B$16.27B
Sector
HealthConsumer Cyclical
52-Week High
$119.34$202.09
52-Week Low
$83.89$135.42
Enterprise Value
$6.60B$20.17B
Dividend Yield
0.35%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BioNTech SE - ADR

BioNTech (BNTX) trades at $93.27, up 0.51% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 revenue of $106 million, missing expectations, and lowered its full-year sales outlook due to weak COVID-19 vaccine demand. Despite negative net income margins and cash outflows, BNTX maintains a strong cash position of $16.78 billion and is advancing its oncology pipeline with 14 pivotal clinical trials.

The outlook is mixed: analyst consensus is strongly bullish with a $121 price target, but declining COVID revenue and ongoing losses pose significant risks. Investment opportunity hinges on successful pipeline development, while near-term headwinds from vaccine demand softness and leadership transition require careful monitoring.

Hyatt Hotels Corporation

Hyatt Hotels Corp (H) trades at $176.29, up 3.65% today, with a bearish technical outlook but strong recent earnings beats. The stock shows a high P/E of 213.14 and modest net margin of 1.1%, while cash flow trends are volatile. Analyst consensus is mixed with a $199.55 price target, and recent news highlights valuation concerns amid growth initiatives.

Outlook balances operational momentum from fee growth and RevPAR gains against rich valuation and debt risks. Investment opportunity lies in sustained travel demand, but risks include project delays, regional weakness, and high leverage. The stock requires patience for growth to justify premium multiples.

Returns comparison

Trailing returns across standard periods

About BioNTech SE - ADR

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.

Read more on BNTX

About Hyatt Hotels Corporation

Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.

Read more on H